Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by EG 427

News headline image
EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint
From EG 427
Via GlobeNewswire
News headline image
EG 427 Receives U.S. FDA Fast Track Designation for EG110A DNA Medicine in Neurogenic Bladder Patients
From EG 427
Via GlobeNewswire
News headline image
EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients
From EG 427
Via GlobeNewswire
News headline image
EG 427 highlights at ASGCT major advances made with its HERMES platform in neurology using versatile non-replicative herpes vectors
From EG 427
Via GlobeNewswire
News headline image
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
From EG 427
Via GlobeNewswire
News headline image
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development
From EG 427
Via GlobeNewswire
News headline image
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
From EG 427
Via GlobeNewswire
News headline image
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
From EG 427
Via GlobeNewswire
News headline image
EG 427 announces final Series A closing, achieving €18 million in total funds raised
From EG 427
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.